Liposomal Doxorubicin and Docetaxel in Metastatic Breast Cancer

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

Evaluation of safety and efficacy of a treatment associating Pegylated Liposomal Doxorubicin + Docetaxel in patients with metastatic breast cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ARCAGY/ GINECO GROUP
• Treatments: Docetaxel; Doxorubicin; Liposomal doxorubicin

Criteria

Inclusion Criteria:

• first metastatic chemo line

• presence of measurable or bone lesion

• at least one lesion outside the radiated areas

• can have previously received hormonotherapy, chemotherapy in adjuvant phase, radiotherapy if older than 4 weeks

Exclusion Criteria:

• only local tumoral progression

• symptomatic cerebral metastasis

• neuropathy > NCI-CTC 2

• previous cancer within 10 years _ previous cancer within 10 years